Literature DB >> 17263635

Evaluation of cellular immune responses in subjects chronically infected with HIV type 1.

Tong-Ming Fu1, Sheri A Dubey, Devan V Mehrotra, Daniel C Freed, Wendy L Trigona, Lisa Adams-Muhler, James H Clair, Thomas G Evans, Roy Steigbigel, Jeffrey M Jacobson, Paul A Goepfert, Mark J Mulligan, Spyros A Kalams, Charles Rinaldo, Lan Zhu, Kara S Cox, Liming Guan, Romnie Long, Natasha Persaud, Michael J Caulfield, Jerald C Sadoff, Emilio A Emini, Scott Thaler, John W Shiver.   

Abstract

The importance of host cellular immune responses, particularly CD8(+) cytotoxic T-lymphocyte (CTL) responses, in control of human immunodeficiency virus type 1 (HIV-1) infection has been demonstrated in many clinical studies. These studies, along with vaccination challenge studies in rhesus macaques, indicate the importance of cellular immune responses against HIV-1. Toward this end, we evaluated anti-HIV-1 cellular immune responses in a cohort of 54 subjects who were chronically infected with HIV-1. By validation of IFN-gamma ELISpot assay, we established a dual cut-off criterion for scoring a positive response. The magnitude and frequency of cellular immune responses were measured against HIV-1 antigens (Gag, Pol, Nef, Rev, and Tat), using synthetic peptides as antigens in ELISpot assay. Here we showed that HIV-1 Gag, Pol, and Nef were frequent targets of T cell responses in these subjects, whereas Tat and Rev were less frequently recognized. We further evaluated the possible association between host cellular immune responses and corresponding plasma viral loads in this cohort. By performing ranking correlation analysis, we demonstrated a positive correlation between host viral loads and ELISpot responses of HIV Gag and Pol in untreated subjects. For the subjects under antiviral regimens, however, we did not find any significant association. Our findings suggest that the high levels of ELISpot responses in chronically infected subjects were reflective of their persistent viral infection.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17263635     DOI: 10.1089/aid.2006.0114

Source DB:  PubMed          Journal:  AIDS Res Hum Retroviruses        ISSN: 0889-2229            Impact factor:   2.205


  22 in total

1.  The Breadth of Expandable Memory CD8+ T Cells Inversely Correlates with Residual Viral Loads in HIV Elite Controllers.

Authors:  Zaza M Ndhlovu; Eleni Stampouloglou; Kevin Cesa; Orestes Mavrothalassitis; Donna Marie Alvino; Jonathan Z Li; Shannon Wilton; Daniel Karel; Alicja Piechocka-Trocha; Huabiao Chen; Florencia Pereyra; Bruce D Walker
Journal:  J Virol       Date:  2015-08-12       Impact factor: 5.103

2.  Retracing our STEP towards a successful CTL-based HIV-1 vaccine.

Authors:  Otto O Yang
Journal:  Vaccine       Date:  2008-02-27       Impact factor: 3.641

Review 3.  Post-step modifications for research on HIV vaccines.

Authors:  Lawrence Corey; M Juliana McElrath; James G Kublin
Journal:  AIDS       Date:  2009-01-02       Impact factor: 4.177

4.  Clade A HIV-1 Gag-specific T cell responses are frequent but do not correlate with viral loads in a cohort of treatment-naive HIV-infected individuals living in Guinea-Bissau.

Authors:  Kristoffer Jarlov Jensen; Victor Raúl Gómez Román; Sanne Skov Jensen; Christian Leo-Hansen; Ingrid Karlsson; Terese Lea Katzenstein; Candida Medina Rodrigues; Sanne Jespersen; Christoph Mikkel Janitzek; David da Silva Té; Peter Hayes; Anders Fomsgaard
Journal:  Clin Vaccine Immunol       Date:  2012-10-17

5.  Safety and immunogenicity of the Merck adenovirus serotype 5 (MRKAd5) and MRKAd6 human immunodeficiency virus type 1 trigene vaccines alone and in combination in healthy adults.

Authors:  Clayton Harro; Xiao Sun; Jon E Stek; Randi Y Leavitt; Devan V Mehrotra; Fubao Wang; Andrew J Bett; Danilo R Casimiro; John W Shiver; Mark J DiNubile; Erin Quirk
Journal:  Clin Vaccine Immunol       Date:  2009-07-15

6.  Sustained transgene expression despite T lymphocyte responses in a clinical trial of rAAV1-AAT gene therapy.

Authors:  Mark L Brantly; Jeffrey D Chulay; Lili Wang; Christian Mueller; Margaret Humphries; L Terry Spencer; Farshid Rouhani; Thomas J Conlon; Roberto Calcedo; Michael R Betts; Carolyn Spencer; Barry J Byrne; James M Wilson; Terence R Flotte
Journal:  Proc Natl Acad Sci U S A       Date:  2009-08-12       Impact factor: 11.205

7.  Peptide impurities in commercial synthetic peptides and their implications for vaccine trial assessment.

Authors:  Jeffrey R Currier; Lynee M Galley; Holger Wenschuh; Vivian Morafo; Silvia Ratto-Kim; Clive M Gray; Leonard Maboko; Michael Hoelscher; Mary A Marovich; Josephine H Cox
Journal:  Clin Vaccine Immunol       Date:  2007-12-12

8.  Safety and immunogenicity of adenovirus-vectored near-consensus HIV type 1 clade B gag vaccines in healthy adults.

Authors:  Clayton D Harro; Michael N Robertson; Michelle A Lally; Lori D O'Neill; Srilatha Edupuganti; Paul A Goepfert; Mark J Mulligan; Frances H Priddy; Sheri A Dubey; Lisa S Kierstead; Xiao Sun; Danilo R Casimiro; Mark J DiNubile; John W Shiver; Randi Y Leavitt; Devan V Mehrotra
Journal:  AIDS Res Hum Retroviruses       Date:  2009-01       Impact factor: 2.205

9.  Intranasal vaccination of recombinant adeno-associated virus encoding receptor-binding domain of severe acute respiratory syndrome coronavirus (SARS-CoV) spike protein induces strong mucosal immune responses and provides long-term protection against SARS-CoV infection.

Authors:  Lanying Du; Guangyu Zhao; Yongping Lin; Hongyan Sui; Chris Chan; Selene Ma; Yuxian He; Shibo Jiang; Changyou Wu; Kwok-Yung Yuen; Dong-Yan Jin; Yusen Zhou; Bo-Jian Zheng
Journal:  J Immunol       Date:  2008-01-15       Impact factor: 5.422

10.  Diverse cross-reactive potential and Vbeta gene usage of an epitope-specific cytotoxic T-lymphocyte population in monkeys immunized with diverse human immunodeficiency virus type 1 Env immunogens.

Authors:  Sandrine L Hulot; Michael S Seaman; Pritha Sen; Patrick A Autissier; Edwin R Manuel; Norman L Letvin
Journal:  J Virol       Date:  2009-07-29       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.